These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28751415)

  • 1. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Ghosh S; Breitscheidel L; Lazarevic N; Martin A; Hafkin J; Hittel N
    Eur Respir J; 2021 May; 57(5):. PubMed ID: 33243846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.
    Esposito S; D'Ambrosio L; Tadolini M; Schaaf HS; Caminero Luna J; Marais B; Centis R; Dara M; Matteelli A; Blasi F; Migliori GB
    Eur Respir J; 2014 Sep; 44(3):811-5. PubMed ID: 24833763
    [No Abstract]   [Full Text] [Related]  

  • 6. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
    Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
    Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
    Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
    Hoffmann H; Kohl TA; Hofmann-Thiel S; Merker M; Beckert P; Jaton K; Nedialkova L; Sahalchyk E; Rothe T; Keller PM; Niemann S
    Am J Respir Crit Care Med; 2016 Feb; 193(3):337-40. PubMed ID: 26829425
    [No Abstract]   [Full Text] [Related]  

  • 12. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
    Mok J; Kang H; Koh WJ; Jhun BW; Yim JJ; Kwak N; Lee T; Kang B; Jeon D
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31285308
    [No Abstract]   [Full Text] [Related]  

  • 18. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
    Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
    Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.